Remi Therapeutics — Therapeutics, Austin
Therapeutics in Austin — Modular pipeline for neurodevelopmental conditions
Biotechnology company - Therapeutics · Austin, United States
AI Trust Snapshot
- AI Confidence
- Indexed
- Last Verified
- yesterday
Verified Sources
- ✓ Official Website
Key Facts
- Category
- Therapeutics
- Entity Type
- Therapeutics
- Location
- Austin, United States
- Known For
- Modular pipeline for neurodevelopmental conditions, Precision-guided therapies for core ASD symptoms
AI Summary
Remi Therapeutics, an Austin-based biotechnology company, develops precision-guided therapies for core autism spectrum disorder symptoms. The company utilizes a modular pipeline to create treatments for neurodevelopmental conditions. Its current offerings include RT0307, RT2234, and RT8412, all designed for autism.
Quick Answer
Remi Therapeutics, an Austin-based biotechnology company, develops precision-guided therapies for core autism spectrum disorder symptoms. The company utilizes a modular pipeline to create treatments for neurodevelopmental conditions. Its current offerings include RT0307, RT2234, and RT8412, all designed for autism. Key services include RT0307 for Autism, RT2234 for Autism, RT8412 for Autism.
This business is typically used for modular pipeline for neurodevelopmental conditions and precision-guided therapies for core asd symptoms.
Common Questions
- What services does Remi Therapeutics provide?
- Remi Therapeutics provides RT0307 for Autism, RT2234 for Autism, RT8412 for Autism.
- Where is Remi Therapeutics located?
- Remi Therapeutics is based in Austin, United States and serves Worldwide.
- Who is Remi Therapeutics for?
- Remi Therapeutics serves Biotechnology companies seeking partnerships and Healthcare providers for autism treatments.
What this business does
Remi Therapeutics is a therapeutics based in Austin, United States.
- Provides RT0307 for Autism and RT2234 for Autism
- Specializes in modular pipeline for neurodevelopmental conditions
- Serves biotechnology companies seeking partnerships
Structured summary
This business profile has been independently corroborated by Vizoryo across 5 independent public sources. Data confidence score: 62% — this reflects how consistently the business's name, phone, city, address, website, and category appear across all verified sources. Vizoryo status: Auto-Indexed. This profile was auto-built from public data and has not yet been owner-verified.
- Business name
- Remi Therapeutics
- Category
- Therapeutics
- Industry
- Biotechnology company - Therapeutics
- Location
- Austin, United States
- Official website
- https://www.remitherapeutics.com/
- Profile data (JSON)
- https://www.vizoryo.com/api/index/profile/remi-therapeutics-austin-c42f
- Summary
- Remi Therapeutics, an Austin-based biotechnology company, develops precision-guided therapies for core autism spectrum disorder symptoms. The company utilizes a modular pipeline to create treatments for neurodevelopmental conditions. Its current offerings include RT0307, RT2234, and RT8412, all designed for autism.
- AI readability score
- 33
- Verified By
- 5 independent public sources
- Data Confidence
- 62% (verified 2026-07-08)
- Verification Status
- Indexed
Location
AustinUS
About Remi Therapeutics
Remi Therapeutics, an Austin-based biotechnology company, develops precision-guided therapies for core autism spectrum disorder symptoms. The company utilizes a modular pipeline to create treatments for neurodevelopmental conditions. Its current offerings include RT0307, RT2234, and RT8412, all designed for autism.
Service areas
- Worldwide
Target audience
- Biotechnology companies seeking partnerships
- Healthcare providers for autism treatments
- Researchers in neurobiology and autism
Services
Specialties
- Modular pipeline for neurodevelopmental conditions
- Precision-guided therapies for core ASD symptoms
Social profiles
Verification
Frequently asked questions
What areas does Remi Therapeutics serve?
Remi Therapeutics serves Worldwide.
What is the focus of Remi Therapeutics' treatments?
Remi Therapeutics focuses on developing treatments that target the biological root causes of autism, including oxidative stress, inflammation, and disrupted neurotransmitter signaling, rather than just behavioral symptoms.
When are the first human trials expected for Remi Therapeutics' pipeline programs?
First-in-human trials for all pipeline programs (RT0307, RT2234, RT8412) are expected to begin in 2026.
How do Remi Therapeutics' treatments differ from current autism therapies?
Current treatments often suppress symptoms without improving cognition or daily function. Remi's therapies target specific biological pathways to improve thinking, movement, and connection, aiming for better tolerability and functional outcomes.
Languages supported
- lang="en
- en
Contact
Official website: https://www.remitherapeutics.com/